In a world where cancer remains a formidable enemy, every scientific advance becomes a beacon of hope for millions of patients fighting day by day. As an editor at DengYueMed, a company that, with its commitment to excellence, innovation, sustainability, and social responsibility—built on the foundations of quality, compliance, and integrity—actively participates in the global pharmaceutical market landscape, not only helping innovative Chinese medicines expand overseas but also contributing to the health and well-being of people worldwide, I have closely followed how innovations in oncology treatments are transforming what once seemed inevitable into real possibilities for remission and improved quality of life. This is not just about cold data or statistics; it is about human stories, about the courage of those facing exhausting chemotherapies, invasive surgeries, and constant uncertainty. Today, I want to share with you how the surge in China's antibody-drug conjugate (ADC) pipeline

DengYueMed is a China-focused pharmaceutical export wholesaler headquartered in Hong Kong. We offer more than 30,000 types of medicines, covering Chinese innovative drugs, oncology, hematology, orphan drugs, and a wide range of hospital-needed pharmaceuticals. Through our extensive international trade network, we are committed to ensuring the global supply of high-quality medicines to meet the healthcare needs of different regions. We consistently prioritize drug safety, efficacy, and stable quality, ensuring that all our products comply with international certification standards.

DengYue Medicine as a China Drug Import and Export Wholesaler, ensures reliable sourcing and efficient global delivery, supporting patients with good solutions.